Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening

Igor A. Schepetkin, Andrey Ivanovich Khlebnikov, Liliya N. Kirpotina, Mark T. Quinn

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Anthrax lethal factor (LF) is a key virulence factor of anthrax lethal toxin. We screened a chemolibrary of 10 000 drug-like molecules for their ability to inhibit LF and identified 18 novel small molecules with potent LF inhibitory activity. Three additional LF inhibitors were identified through further structure-activity relationship (SAR) analysis. All 21 compounds inhibited LF with an IC50 range of 0.8 to 11 μM, utilizing mixed-mode competitive inhibition. An evaluation of inhibitory activity against a range of unrelated proteases showed relatively high specificity for LF. Furthermore, pharmacophore modeling of these compounds showed a high degree of similarity to the model published by Panchal et al. (Nat. Struct. Mol. Biol. 2004, 11, 67-72), indicating that the conformational features of these inhibitors are structurally compatible with the steric constraints of the substrate-binding pocket. These novel LF inhibitors and the structural scaffolds identified as important for inhibitory activity represent promising leads to pursue for further LF inhibitor development.

Original languageEnglish
Pages (from-to)5232-5244
Number of pages13
JournalJournal of Medicinal Chemistry
Volume49
Issue number17
DOIs
Publication statusPublished - 24 Aug 2006
Externally publishedYes

Fingerprint

Screening
Throughput
Molecules
Virulence Factors
Structure-Activity Relationship
Scaffolds
Inhibitory Concentration 50
Peptide Hydrolases
Substrates
Pharmaceutical Preparations
anthrax toxin

ASJC Scopus subject areas

  • Organic Chemistry

Cite this

Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening. / Schepetkin, Igor A.; Khlebnikov, Andrey Ivanovich; Kirpotina, Liliya N.; Quinn, Mark T.

In: Journal of Medicinal Chemistry, Vol. 49, No. 17, 24.08.2006, p. 5232-5244.

Research output: Contribution to journalArticle

@article{5fbfa5f94e50479ca3cf97e87176ef40,
title = "Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening",
abstract = "Anthrax lethal factor (LF) is a key virulence factor of anthrax lethal toxin. We screened a chemolibrary of 10 000 drug-like molecules for their ability to inhibit LF and identified 18 novel small molecules with potent LF inhibitory activity. Three additional LF inhibitors were identified through further structure-activity relationship (SAR) analysis. All 21 compounds inhibited LF with an IC50 range of 0.8 to 11 μM, utilizing mixed-mode competitive inhibition. An evaluation of inhibitory activity against a range of unrelated proteases showed relatively high specificity for LF. Furthermore, pharmacophore modeling of these compounds showed a high degree of similarity to the model published by Panchal et al. (Nat. Struct. Mol. Biol. 2004, 11, 67-72), indicating that the conformational features of these inhibitors are structurally compatible with the steric constraints of the substrate-binding pocket. These novel LF inhibitors and the structural scaffolds identified as important for inhibitory activity represent promising leads to pursue for further LF inhibitor development.",
author = "Schepetkin, {Igor A.} and Khlebnikov, {Andrey Ivanovich} and Kirpotina, {Liliya N.} and Quinn, {Mark T.}",
year = "2006",
month = "8",
day = "24",
doi = "10.1021/jm0605132",
language = "English",
volume = "49",
pages = "5232--5244",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "17",

}

TY - JOUR

T1 - Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening

AU - Schepetkin, Igor A.

AU - Khlebnikov, Andrey Ivanovich

AU - Kirpotina, Liliya N.

AU - Quinn, Mark T.

PY - 2006/8/24

Y1 - 2006/8/24

N2 - Anthrax lethal factor (LF) is a key virulence factor of anthrax lethal toxin. We screened a chemolibrary of 10 000 drug-like molecules for their ability to inhibit LF and identified 18 novel small molecules with potent LF inhibitory activity. Three additional LF inhibitors were identified through further structure-activity relationship (SAR) analysis. All 21 compounds inhibited LF with an IC50 range of 0.8 to 11 μM, utilizing mixed-mode competitive inhibition. An evaluation of inhibitory activity against a range of unrelated proteases showed relatively high specificity for LF. Furthermore, pharmacophore modeling of these compounds showed a high degree of similarity to the model published by Panchal et al. (Nat. Struct. Mol. Biol. 2004, 11, 67-72), indicating that the conformational features of these inhibitors are structurally compatible with the steric constraints of the substrate-binding pocket. These novel LF inhibitors and the structural scaffolds identified as important for inhibitory activity represent promising leads to pursue for further LF inhibitor development.

AB - Anthrax lethal factor (LF) is a key virulence factor of anthrax lethal toxin. We screened a chemolibrary of 10 000 drug-like molecules for their ability to inhibit LF and identified 18 novel small molecules with potent LF inhibitory activity. Three additional LF inhibitors were identified through further structure-activity relationship (SAR) analysis. All 21 compounds inhibited LF with an IC50 range of 0.8 to 11 μM, utilizing mixed-mode competitive inhibition. An evaluation of inhibitory activity against a range of unrelated proteases showed relatively high specificity for LF. Furthermore, pharmacophore modeling of these compounds showed a high degree of similarity to the model published by Panchal et al. (Nat. Struct. Mol. Biol. 2004, 11, 67-72), indicating that the conformational features of these inhibitors are structurally compatible with the steric constraints of the substrate-binding pocket. These novel LF inhibitors and the structural scaffolds identified as important for inhibitory activity represent promising leads to pursue for further LF inhibitor development.

UR - http://www.scopus.com/inward/record.url?scp=33747519634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747519634&partnerID=8YFLogxK

U2 - 10.1021/jm0605132

DO - 10.1021/jm0605132

M3 - Article

VL - 49

SP - 5232

EP - 5244

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 17

ER -